Literature DB >> 20484436

Delivery of Na/I symporter gene into skeletal muscle using nanobubbles and ultrasound: visualization of gene expression by PET.

Yukiko Watanabe1, Sachiko Horie, Yoshihito Funaki, Youhei Kikuchi, Hiromichi Yamazaki, Keizo Ishii, Shiro Mori, Georges Vassaux, Tetsuya Kodama.   

Abstract

UNLABELLED: The development of nonviral gene delivery systems is essential in gene therapy, and the use of a minimally invasive imaging methodology can provide important clinical endpoints. In the current study, we present a new methodology for gene therapy-a delivery system using nanobubbles and ultrasound as a nonviral gene delivery method. We assessed whether the gene transfer allowed by this methodology was detectable by PET and bioluminescence imaging.
METHODS: Two kinds of reported vectors (luciferase and human Na/I symporter [hNIS]) were transfected or cotransfected into the skeletal muscles of normal mice (BALB/c) using the ultrasound-nanobubbles method. The kinetics of luciferase gene expression were analyzed in vivo using bioluminescence imaging. At the peak of gene transfer, PET of hNIS expression was performed using our recently developed PET scanner, after (124)I injection. The imaging data were confirmed using reverse-transcriptase polymerase chain reaction amplification, biodistribution, and a blocking study. The imaging potential of the 2 methodologies was evaluated in 2 mouse models of human pathology (McH/lpr-RA1 mice showing vascular disease and C57BL/10-mdx Jic mice showing muscular dystrophy).
RESULTS: Peak luciferase gene activity was observed in the skeletal muscle 4 d after transfection. On day 2 after hNIS and luciferase cotransfection, the expression of these genes was confirmed by reverse-transcriptase polymerase chain reaction on a muscle biopsy. PET of the hNIS gene, biodistribution, the blocking study, and autoradiography were performed on day 4 after transfection, and it was indicated that hNIS expression was restricted to the site of plasmid administration (skeletal muscle). Similar localized PET and (124)I accumulation were successfully obtained in the disease-model mice.
CONCLUSION: The hNIS gene was delivered into the skeletal muscle of healthy and disease-model mice by the ultrasound-nanobubbles method, and gene expression was successfully visualized with PET. The combination of ultrasound-nanobubble gene transfer and PET may be applied to gene therapy clinical protocols.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20484436     DOI: 10.2967/jnumed.109.074443

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  17 in total

Review 1.  Theranostic applications of nanomaterials in cancer: drug delivery, image-guided therapy, and multifunctional platforms.

Authors:  Alicia Fernandez-Fernandez; Romila Manchanda; Anthony J McGoron
Journal:  Appl Biochem Biotechnol       Date:  2011-09-27       Impact factor: 2.926

Review 2.  Leveraging the power of ultrasound for therapeutic design and optimization.

Authors:  Charles F Caskey; Xiaowen Hu; Katherine W Ferrara
Journal:  J Control Release       Date:  2011-07-30       Impact factor: 9.776

3.  Image-guided tumor-selective radioiodine therapy of liver cancer after systemic nonviral delivery of the sodium iodide symporter gene.

Authors:  Kathrin Klutz; Michael J Willhauck; Christian Dohmen; Nathalie Wunderlich; Kerstin Knoop; Christian Zach; Reingard Senekowitsch-Schmidtke; Franz-Josef Gildehaus; Sibylle Ziegler; Sebastian Fürst; Burkhard Göke; Ernst Wagner; Manfred Ogris; Christine Spitzweg
Journal:  Hum Gene Ther       Date:  2011-10-11       Impact factor: 5.695

4.  Multiparameter evaluation of in vivo gene delivery using ultrasound-guided, microbubble-enhanced sonoporation.

Authors:  Galina Shapiro; Andrew W Wong; Maxim Bez; Fang Yang; Sarah Tam; Lisa Even; Dmitriy Sheyn; Shiran Ben-David; Wafa Tawackoli; Gadi Pelled; Katherine W Ferrara; Dan Gazit
Journal:  J Control Release       Date:  2015-12-10       Impact factor: 9.776

5.  Epidermal growth factor receptor-targeted (131)I-therapy of liver cancer following systemic delivery of the sodium iodide symporter gene.

Authors:  Kathrin Klutz; David Schaffert; Michael J Willhauck; Geoffrey K Grünwald; Rudolf Haase; Nathalie Wunderlich; Christian Zach; Franz J Gildehaus; Reingard Senekowitsch-Schmidtke; Burkhard Göke; Ernst Wagner; Manfred Ogris; Christine Spitzweg
Journal:  Mol Ther       Date:  2011-01-18       Impact factor: 11.454

6.  In situ bone tissue engineering via ultrasound-mediated gene delivery to endogenous progenitor cells in mini-pigs.

Authors:  Maxim Bez; Dmitriy Sheyn; Wafa Tawackoli; Pablo Avalos; Galina Shapiro; Joseph C Giaconi; Xiaoyu Da; Shiran Ben David; Jayne Gavrity; Hani A Awad; Hyun W Bae; Eric J Ley; Thomas J Kremen; Zulma Gazit; Katherine W Ferrara; Gadi Pelled; Dan Gazit
Journal:  Sci Transl Med       Date:  2017-05-17       Impact factor: 17.956

7.  Assessment of the biodistribution of an [(18) F]FDG-loaded perfluorocarbon double emulsion using dynamic micro-PET in rats.

Authors:  Mario L Fabiilli; Morand R Piert; Robert A Koeppe; Phillip S Sherman; Carole A Quesada; Oliver D Kripfgans
Journal:  Contrast Media Mol Imaging       Date:  2013 Jul-Aug       Impact factor: 3.161

8.  Optimization of acoustic liposomes for improved in vitro and in vivo stability.

Authors:  Nicolas Sax; Tetsuya Kodama
Journal:  Pharm Res       Date:  2012-09-01       Impact factor: 4.200

9.  Nanobubbles for enhanced ultrasound imaging of tumors.

Authors:  Tinghui Yin; Ping Wang; Rongqin Zheng; Bowen Zheng; Du Cheng; Xinling Zhang; Xintao Shuai
Journal:  Int J Nanomedicine       Date:  2012-02-22

10.  Normalisation to blood activity is required for the accurate quantification of Na/I symporter ectopic expression by SPECT/CT in individual subjects.

Authors:  Peggy Richard-Fiardo; Philippe R Franken; Audrey Lamit; Robert Marsault; Julien Guglielmi; Béatrice Cambien; Fanny Graslin; Sabine Lindenthal; Jacques Darcourt; Thierry Pourcher; Georges Vassaux
Journal:  PLoS One       Date:  2012-03-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.